Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This ...
Medtronic recently announced that the U.S. Food and Drug Administration (FDA) has approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. Medtronic’s DBS ...
Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...
Medtronic ($MDT) has earned a CE mark for its SureTune2 software. The tech offers physicians patient-specific visualizations which help them to “tune” a patient ...
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN, March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
At Samsung Developer Conference 2019 today, Medtronic and Samsung showed off a Galaxy smartphone app, Patient Programmer, that allows patients to manage their own therapy for Parkinson’s disease.
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing "This is the only directional lead with built-in sensing capabilities," said Jens Volkmann, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback